Bright Minds Biosciences Inc.
DRUG
CNSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -5.35% | 106.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.89% | 127.11% | |||
| Operating Income | 26.89% | -127.11% | |||
| Income Before Tax | 77.55% | -38.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 77.55% | -38.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 77.55% | -38.60% | |||
| EBIT | 26.89% | -127.11% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 78.10% | -12.17% | |||
| Normalized Basic EPS | 78.09% | -12.17% | |||
| EPS Diluted | 78.10% | -12.17% | |||
| Normalized Diluted EPS | 78.09% | -12.17% | |||
| Average Basic Shares Outstanding | 2.51% | 23.56% | |||
| Average Diluted Shares Outstanding | 2.51% | 23.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||